Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5330MR)

This product GTTS-WQ5330MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Lymphoma, B cell research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5330MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2972MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ1340MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-806
GTTS-WQ15312MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ3211MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ11413MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ14256MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ3470MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ6276MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW